Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients

Contributed by: PR Newswire

Tags

Hansa-Biopharma-AB

More Like This

Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results